Allogene Therapeutics will report earnings after the market closes. View Calendar The market is expecting a ±9.2% move after earnings are reported. The average move for the past 4 quarters of earnings has been ±8.4%. View Expected Move (Conf Call: May 13 5:00 PM)
$ALLO Earnings May 13 AMC. 15-May-26 Straddle Implies ±9.2% Move vs Prev. Move -2.8%
Allogene Therapeutics trades 2,808 contracts. The company has the following event: Interim Futility Analysis of MRD Clearance from the Pivotal Phase 2 ALPHA3 Trial with Cemacabtagene Ansegedleucel (Cema-Cel) in First-Line (1L) Consolidation Large B-Cell Lymphoma (LBCL) between Apr 1, 2026 and Jun 30, 2026.
Allogene Therapeutics trades 2,404 contracts. The company has the following event: Interim Futility Analysis of MRD Clearance from the Pivotal Phase 2 ALPHA3 Trial with Cemacabtagene Ansegedleucel (Cema-Cel) in First-Line (1L) Consolidation Large B-Cell Lymphoma (LBCL) between Apr 1, 2026 and Jun 30, 2026. News: Allogene Therapeutics Announces Proposed Public Offering of $175 Million of Common Stock
